Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) has signed a joint research agreement with Higashiosaka City Medical Center (Location: Higashi-Osaka, Osaka, Chairman: Kazuhiro Taniguchi). With the conclusion of this agreement, Craif and Surgery Department at Higashiosaka City Medical Center will start a study to “Investigate Clinical Significance of Urinary Exosomes in Patients with Lung Cancer”(Principal Investigator: Masahiko Higashiyama).

■Outline of Research
This study aims to identify biomarkers that can be translated into routine clinical practice by examining urinary miRNA before and after treatment for lung cancer patients, and analyze for lung cancer-specific biomarkers. By comparing urinary miRNAs in benign and malignant lung cancer patients, we will explore their usefulness as biomarkers. In addition, we aim to clarify the correlation between urinary miRNA and lung cancer histology, postoperative complications, patient background factors, and response rate to antineoplastic.